Paenibacillus polymyxa

Other Names

Aerobacillus polymyxaBacillus polymyxaClostridium polymyxaGranulobacter polymyxa

Synopsis

Identity

Nomenclature and Taxonomic Classification

Paenibacillus polymyxa is a Gram-positive, rod-shaped, endospore-forming bacterium belonging to the genus Paenibacillus in the family Paenibacillaceae, previously classified as Bacillus polymyxa. It sits within the lineage: Bacteria → Bacillota → Bacilli → Bacillales → Paenibacillaceae → Paenibacillus.

The organism carries a richly layered nomenclatural history. Paenibacillus polymyxa was first described in 1880 by Albert Prazmowski as Clostridium polymyxa, based on isolates from soil environments, where it was noted for its spore-forming, anaerobic growth. In 1889, it was reclassified as Bacillus polymyxa by Émile Macé, aligning it with aerobic, endospore-forming rods, a taxonomy that persisted for over a century and facilitated early investigations into its ecological roles. In 1993, a new genus, Paenibacillus, was established through comparative 16S rRNA sequence analysis of the Bacillus genus, leading to the current designation of P. polymyxa. This reclassification was officially approved and announced by the International Committee on Systematic Bacteriology in 1994, and the family was designated Paenibacillaceae.

The distinction was made using comparative analysis of the 16S rRNA gene sequence of three different bacilli which showed enough phylogenetic distance from Bacillus subtilis to warrant a new genus; Paenibacillus (paene + Bacillus) means "almost Bacillus" in Latin. The species epithet polymyxa originates from the Greek words poly (many) and myxa (slime or mucus), alluding to the bacterium's characteristic production of abundant mucoid colonies.

Synonyms documented in formal taxonomic records include Clostridium polymyxa Prazmowski 1880, Bacillus polymyxa Macé 1889, and Aerobacillus polymyxa Donker 1926. The formal current authority citation is Paenibacillus polymyxa (Prazmowski 1880) Ash et al. 1994.

Natural Sources and Ecological Niches

P. polymyxa is a facultative anaerobe commonly isolated from soil, plant roots, and diverse environmental niches such as rhizospheres of crops like wheat, barley, and beans. It is found in soil, plant tissues, marine sediments, and hot springs. P. polymyxa is a frequent inhabitant of various niches including soil, plant rhizospheres and plant tissues, but also digestive tracts of different animals; it has further been occasionally found in samples of seawater and fermented foods, and is also an inhabitant of the International Space Station.

As a prominent plant growth-promoting rhizobacterium (PGPR), it colonizes plant roots, forms biofilms, and invades intercellular spaces without systemic spread.

Physical and Physiological Characteristics

In its vegetative state, microorganisms are generally 1.8 to 2.2 μm in length and 0.6 to 0.8 μm in width. Colonies are mucous, slimy, and tend to spread; the bacteria are generally aerobes and are capable of nitrogen fixation under anaerobic conditions. The endospores of P. polymyxa exhibit remarkable resilience, enabling them to withstand harsh environmental conditions such as high temperatures, biocides, pressure, and UV radiation, and this durability enables the endospores to survive processes like pasteurization and persist in industrial equipment. Endospores are stable against acids as low as pH 2.0 and alkali as high as pH 9.0.

Common Forms and Preparations

In commercial and research contexts, P. polymyxa is encountered in several forms:

Dried spore/cell powders: Application of bio-friendly feed additives such as probiotics, prebiotics, and synbiotics are becoming popular dietary supplements with the potential to not only improve growth performance, but in some cases can also enhance immune competence and the overall well-being of fish and crustaceans. P. polymyxa is formulated in this manner and is standardized by colony-forming units (CFU) per gram.
Cell culture supernatants: Methods of preparing a dietary supplement comprising a cell culture supernatant obtained from culturing isolated Paenibacillus polymyxa bacterium have been described in patent literature, with the supernatant comprising at least one antimicrobial compound produced by the organism.
Fermented preparations: Milk can support the growth of P. polymyxa OSY-HG, which produces up to 32 mg paenibacillin/L milk, and fermentation crude extracts have been applied in model food systems such as Vienna sausage to control Listeria innocua.
Water-soluble powders for aquaculture and animal feed: These preparations are standardized to defined CFU counts and added to feed or water at measured concentrations.
Agricultural biofertilizer/biocontrol formulations: P. polymyxa is the basis for several commercial formulations against plant pathogens.

Taxonomic History and Discovery

By the mid-20th century, studies had established B. polymyxa as a free-living nitrogen fixer, with research in the 1960s demonstrating its ability to assimilate atmospheric N₂ under anaerobic conditions, producing up to 150 μg of nitrogen per mL in culture — key findings that highlighted its potential in soil fertility.

Polymyxins were discovered in the 1940s to be cyclic lipodecapeptide antibiotics and were originally derived from Paenibacillus polymyxa as the products of fermentation in the form of amphipathic lipopeptide molecules; they were recognized for therapeutic use in the 1950s.

In nature, P. polymyxa (formerly known as Bacillus polymyxa), is famous for its production of antimicrobial lipopeptides, the polymyxins, which were described as early as the 1940s and demonstrated to have very strong growth inhibitory activity against Gram-negative bacteria.

Two strains, P. polymyxa SC2 and P. polymyxa E681, have had their entire genomes sequenced, which has greatly accelerated mechanistic and applied research since the early 2000s.

Traditional and Historical Use

Paenibacillus polymyxa does not appear in any documented tradition of human medicine as a named botanical or microbial preparation. Unlike many botanical supplements, this organism was not deliberately isolated or consciously employed in traditional systems of healing (e.g., Traditional Chinese Medicine, Ayurveda, or European folk medicine). Because it is a ubiquitous soil and rhizosphere bacterium, it would have been present without recognition in fermented foods and soil-amended agricultural products throughout human history, but no ethnobotanical or ethnopharmacological record exists for its deliberate use.

Its formal history of intentional use begins in the pharmaceutical sciences of the mid-20th century. The first discovered polymyxin — polymyxin A (formerly known as "aerosporin") — was isolated during the fermentation of Bacillus aerosporus (later renamed Paenibacillus polymyxa). Five types of polymyxins (A, B, C, D, and E) have been identified; polymyxin E (colistin) was introduced to clinical use in 1959 for the treatment of infections caused by Gram-negative bacteria, though by the early 1970s, the use of both polymyxin B and colistin was largely discontinued because of their significant neurotoxicity and nephrotoxicity.

The deliberate use of P. polymyxa whole cells or spore preparations as probiotics for animals — including poultry, fish, and livestock — is a contemporary practice that has emerged primarily in the 21st century, driven by regulatory restrictions on antibiotic growth promoters in animal feed. The search for a natural antimicrobial agent is ongoing and critical because of the rise and rapid proliferation of antibiotic-resistant pathogenic bacteria.

Key Constituents and Active Compounds

P. polymyxa has a wide range of properties, including nitrogen fixation, plant growth promotion, soil phosphorus solubilization, and production of exopolysaccharides, hydrolytic enzymes, antibiotics, and cytokinin. From a supplement-science perspective, the most biologically significant categories of compounds are detailed below.

Polymyxins

Polymyxins are secondary peptide metabolites produced by the Gram-positive bacterium Paenibacillus polymyxa; they belong to an older class of nonribosomal cyclic lipopeptide antibiotics, first discovered in the 1940s. Polymyxins contain conserved components that consist of a d-Phe6-l-Leu7 segment, an N-terminal fatty acyl chain separated by cationic residues (l-α-γ-diaminobutyric acid, Dab), and segments of the polar amino acid threonine (Thr). Polymyxins target the negatively charged outer membrane lipopolysaccharides (LPS) of Gram-negative bacteria. They interact with the LPS molecule, displacing and disrupting Mg²⁺ cross-bridges between anionic LPS molecules in the outer leaflet of the outer membrane, leading to cell envelope destabilization and cell death.

Some strains of P. polymyxa (e.g., DSM32871) produce both polymyxin E and polymyxin P, whereas other strains (e.g., M1) produce only polymyxin P; the polymyxins are excreted into the culture media. By MALDI-TOF mass spectrometry and reversed-phase HPLC, two components of polymyxin P — polymyxin P1 and P2 — bearing molecular masses of 1190.9 Da and 1176.9 Da respectively have been detected and characterized.

Fusaricidins

All kinds of fusaricidins have shown antimicrobial activities against Gram-positive bacteria and the Fusarium genus in vitro. The possible antibacterial mechanism of fusaricidin is that the compound interacts with the cytoplasmic membranes, while the inhibitory mode of action of fusaricidin against fungi remains under investigation. Using liquid chromatography mass spectrometry-based molecular networking approaches, researchers have identified several fusaricidins, including a new variant of m/z 917.5455 with serine in the first position of the hexapeptide.

Paenibacillin (a Lantibiotic)

The newly discovered antimicrobial agent paenibacillin belongs to the group I bacteriocins (lantibiotics) and is active against a broad range of food-borne pathogenic and spoilage bacteria, including Bacillus spp., Clostridium sporogenes, and Lactobacillus spp. Paenibacillin has potential to be used as a natural food preservative to deter pathogen growth in food, pending regulatory approval.

Tridecaptin

Biosynthetic gene clusters (BGCs) encoding polymyxin, fusaricidin B, and tridecaptin have been identified in multiple P. polymyxa strains. Tridecaptin is a linear lipopeptide with activity against Gram-negative bacteria, including those resistant to other antibiotics.

Exopolysaccharides (EPS) — Levan and Paenan

P. polymyxa is known for the production of the exopolysaccharide levan when growing on sucrose, and a heteropolysaccharide named paenan when grown on monomeric carbohydrates such as glucose. During fermentation, P. polymyxa synthesizes levan — a fructose polymer with numerous fructose units in β-(2,6)-linkages. These polysaccharides contribute to root colonization and biofilm formation, with described roles in plant immune elicitation.

Indole-3-Acetic Acid (IAA) and Cytokinins

The plant growth-promoting rhizobacterium P. polymyxa can promote plant growth by producing indole-3-acetic acid (IAA) and volatile compounds. The production of hormones has been suggested to be one of the mechanisms by which plant growth-promoting rhizobacteria stimulate plant growth; P. polymyxa releases the hormone group cytokinins, the identity and quantity of which have been characterized by immunoaffinity chromatography.

Volatile Organic Compounds Including 2,3-Butanediol

P. polymyxa is a non-pathogenic 2,3-butanediol (2,3-BD) producer; the organism was chosen in industrial fermentation studies specifically due to its non-pathogenicity and the ability to synthesize levo-2,3-BD, the more desirable isomer owing to its excellent optical attributes.

Hydrolytic Enzymes

Other useful molecules produced by P. polymyxa include enzymes such as amylases, cellulases, hemicellulases, lipases, pectinases, oxygenases, dehydrogenases, lignin-modifying enzymes, and mutanases, which may have applications for detergents, food and feed, textiles, paper, biofuel, and healthcare.

Siderophores

Siderophores encoded by P. polymyxa increase plant growth in iron-limited conditions by increasing iron availability for the associated plant host and decreasing iron availability for pathogenic organisms.

Mechanisms of Action

Direct Antimicrobial Activity

The antagonistic effect of P. polymyxa against phytopathogens is mainly due to its capability to produce antimicrobial substances, such as peptide antibiotics and antimicrobial proteins. P. polymyxa can produce several kinds of peptide antibiotics, including polymyxins, gavaserin and saltavidin, jolipeptin, gatavalin, and fusaricidins.

Induced Systemic Resistance (ISR) in Plant Hosts

Induced systemic resistance (ISR) elicited by treating seeds or roots with P. polymyxa strain E681 is a possible mechanism for protecting systemic plant tissues from biotic and other environmental stresses. The induced systemic resistance (ISR) is mediated by ethylene and usually responds to certain beneficial and non-pathogenic rhizobacteria.

Nitrogen Fixation

P. polymyxa bacteria are generally aerobes and are capable of nitrogen fixation under anaerobic conditions. Research suggested that P. polymyxa P2b-2R could increase the biomass and seedling height of canola through nitrogen fixation.

Phytohormone Production

The plant growth-promoting traits in isolated strains of P. polymyxa are correlated with several mechanisms, such as the production of organic acids, siderophores, lowering plant ethylene levels by ACC deaminase production, synthesis of plant growth-regulating hormones like indole acetic acid and cytokinins, nitrogen fixation, and phosphate solubilization.

Root Colonization and Biofilm Formation

Biofilms of P. polymyxa growing on plant roots have been shown to produce exopolysaccharides which protect the plants from pathogens. P. polymyxa forms biofilms in the rhizosphere around the root tips.

Immunomodulation in Animal Hosts

When used as a probiotic in animal systems, proposed mechanisms involve interaction with gut-associated lymphoid tissue. Apart from growth benefits, probiotics were also linked with immune modulation in the gut tissue of the host organism; the probiotic–gut interaction is mediated by gut-associated lymphoid tissues (GALT) which comprise MUC proteins, Toll-like receptors (TLRs) present in the immune cells, pro-inflammatory cytokines such as IL-8 and TNF-α, and anti-inflammatory cytokines such as IL-10.

Scientific Evidence by Area of Use

Important framing note: The overwhelming volume of published research on P. polymyxa concerns its roles in agriculture (biocontrol, biofertilization), environmental science, and pharmaceutical antibiotic production. Controlled clinical evidence in humans is absent. The animal-based probiotic research summarized below is largely from non-mammalian species (poultry, fish) or laboratory mammals and cannot be directly extrapolated to human health claims.

1. Antimicrobial Applications — Polymyxin Antibiotics

Evidence type: Well-established pharmaceutical evidence (polymyxin drugs, not the whole organism)

The polymyxin antibiotics colistin and polymyxin B have been recently revitalized as bactericidal drugs due to the increase in bacterial resistance to many commonly used antibiotics. The scarcity of newly introduced antibiotics against resistant Gram-negative bacteria and the recent confirmation of polymyxin safety have favored the use of this antibiotic in the therapy of multidrug-resistant Gram-negative bacterial infections.

It must be clearly distinguished that the clinical evidence for polymyxins pertains to chemically purified and pharmaceutical-grade compounds derived from P. polymyxa fermentation, not the administration of the whole organism. The associated nephrotoxicity and neurotoxicity of polymyxins calls for the development of safer polymyxin therapy; no polymyxin molecule other than polymyxin B and E (colistin) has been thoroughly explored in the literature for clinical relevance.

2. Probiotic Use in Poultry — Animal Evidence

Evidence type: Controlled animal studies (not human clinical trials)

A 2023 study published in Poultry Science examined the dietary effects of P. polymyxa AM20. One hundred twenty Indian river broilers (1-day-old) were randomly divided into 4 groups of 10 chicks each, with 3 replicates. P. polymyxa treatment at 1.5 mg/kg increased body gain by 9% compared to the control due to increased feed intake (P = 0.0001), growth rate (P = 0.0001), and decreased feed conversion ratio. Compared to the control group, P. polymyxa (1.5 mg/kg) enhanced kidney functions in chickens by reducing uric acid and creatinine levels (P = 0.0451). Compared to the control group, alanine aminotransferase and aspartate transaminase levels in the liver were significantly reduced at all P. polymyxa doses. As for the immunoglobulins, the control treatment showed the lowest level of immune response compared to the rest of the treatments, while those added with P. polymyxa had a significantly high immune response. This evidence is preliminary and species-specific; direct translation to human physiology is not supported.

A separate study investigated P. polymyxa in combination with Lactobacillus plantarum in broilers. Screened probiotics Paenibacillus polymyxa BSC10 and Lactobacillus plantarum Lac16 were found to have in vitro anti-Clostridium perfringens activities and could protect Caenorhabditis elegans against C. perfringens infection. Numerous studies have reported that probiotics are beneficial for growth performance and animal health through enhancing intestinal development and nutrients absorption, regulating the mucosal immune system, inhibiting intestinal pathogen colonization and infection, and reshaping intestinal microbiota.

A 2025 study assessed quail supplementation with a combined Bacillus coagulans and P. polymyxa mixture. The study examined the effects of supplementing growing Japanese quail with a Bc+Pp mixture on growth performance, antioxidative activity, immunological status, digestive enzymes, caecal microbiota, and blood chemistry; two hundred 1-week-old meat-type quail chicks were divided into four groups and provided with a feed diet treated with 0.5, 1.0, and 1.5 mg/kg of the Bc+Pp mixture (1:1). Notably, no prior evidence had been found to support the use of Paenibacillus polymyxa in the diet of Japanese quails before this investigation.

3. Probiotic Use in Aquaculture — Animal Evidence

Evidence type: Controlled aquaculture studies (not human clinical trials)

In common carp, the addition of Paenibacillus polymyxa in water could significantly improve survival rate, respiratory burst, and activities of anti-oxidative enzymes after challenge with Aeromonas hydrophila.

A study in Oreochromis niloticus (Nile tilapia) evaluated a bacterial consortium of P. polymyxa HGA4C and Bacillus licheniformis HGA8B. The consortium was incorporated in the diet of Oreochromis niloticus at concentrations of 1 × 10⁶ CFU g⁻¹ (PB1) and 1 × 10⁸ CFU g⁻¹ (PB2). The probiotic feed enhanced growth performance, digestive enzymes, and antioxidant enzymes in the liver and intestine; probiotic-mediated growth enhancement was substantiated by the upregulation of genes GHR-1, GHR-2, IGF-1, and IGF-2; immune-related genes TLR-2, IL-10, and TNF-α were also significantly modulated; and intestinal MUC 2 gene expression revealed mucosal remodeling, while disease resistance of fish challenged with Aeromonas hydrophila was improved.

These are studies in teleost fish under controlled aquaculture conditions. The results are scientifically informative about microbial mechanisms but cannot be used to make claims about human health outcomes.

4. Biocontrol and Plant Pathogen Suppression — Agricultural Evidence

Evidence type: In vitro and in planta studies; multiple field trials

All studied P. polymyxa strains possess capabilities for strong growth antagonism of various bacterial and fungal plant pathogens and parasitic nematodes. P. polymyxa strains offer a biological solution to suppress plant diseases due to their ability to produce some compounds that inhibit plant pathogens and are listed as commercial biocontrol agents by the United States Environmental Protection Agency.

Strain E681 has outstanding growth-promoting effects on barley, cucumber, pepper, sesame, and Arabidopsis thaliana and produces antimicrobial compounds that protect plants against pathogenic fungi, oomycetes, and bacteria. Evidence at the in planta and field-trial level is substantial, with multiple peer-reviewed publications documenting efficacy across diverse crop systems.

5. Food Safety — Preliminary Laboratory Evidence

Evidence type: In vitro and model food studies

Fermentation crude extract of P. polymyxa OSY-HG was applied in a model food (Vienna sausage) to control Listeria innocua, a Listeria monocytogenes surrogate, and the treatment increased Listeria lag time by 2 days at 7°C and at least 6 hours at 37°C. This represents preliminary food safety research, not a clinical or regulatory approval.

6. Potential Medical Antimicrobial Applications — Research-Stage Evidence

Evidence type: In vitro; early-stage translational research

Beyond plant protection, lipopeptides from Paenibacillus spp. have great potential for the treatment of multidrug-resistant (MDR) and human pathogenic bacterial infections. Paenibacillus-derived antimicrobials also have applications in medicine, including polymyxins and fusaricidins, which are nonribosomal lipopeptides first isolated from strains of Paenibacillus polymyxa. This field involves purified compounds in pharmaceutical development pipelines, not whole-organism supplementation.

Genome sequencing has broadened horizons for antibiotic development and other industrial applications beyond agricultural use; at least six gene clusters for the biosynthesis of antibiotics have been discovered, including polymyxin, which was recently reinstated as an antibiotic of last resort against Gram-negative drug-resistant bacteria; three groups of antibiotic synthetases include gene clusters that encode non-ribosomal peptide polymyxin, fusaricidin, and tridecaptin, another for the lantibiotic paenilan, and the third for a polyketide.

Body Systems and Health Areas of Association

Gastrointestinal and Gut Microbiome

In animal models, P. polymyxa administered as a probiotic has been associated with modulation of intestinal microbiota composition, secretion of digestive enzymes, and intestinal mucosal integrity. Isolated probiotic candidate P. polymyxa bacterium was capable of producing extracellular enzymes important for the digestion of food ingredients and tolerated gradient bile juice secreted by the host while effectively producing biofilm — properties considered relevant to probiotic survival in the gastrointestinal tract.

Immune System

Animal studies have documented modulation of both innate and adaptive immunity markers. The body's defence mechanism is also associated with antioxidant enzyme activities; improvements in catalase (CAT), glutathione reductase (GR), glutathione peroxidase (GPx), and superoxide dismutase (SOD) enzymes are also necessary for better body defence against infections. These observations are from fish and poultry models and have not been validated in human clinical trials.

Antimicrobial Defense (Pharmaceutical)

As described above, the purified polymyxin-class antibiotics derived from P. polymyxa fermentation are clinically recognized as last-resort agents for multidrug-resistant Gram-negative infections. Polymyxins (e.g., polymyxin B and colistin) are last-resort antibiotics against resistant Gram-negative bacteria. This application involves pharmaceutical products, not the whole bacterium as a supplement.

Metabolic Parameters (Animal Evidence)

In broiler studies, P. polymyxa supplementation was associated with improved lipid profiles. These are animal-model observations only; no human data currently exist.

Dosage Forms and Reported Dosages in Research

The following dosages have been reported specifically in published studies:

Dietary inclusion in Nile tilapia at concentrations of 1 × 10⁶ CFU g⁻¹ (PB1) and 1 × 10⁸ CFU g⁻¹ (PB2) as a probiotic combination.
Broiler supplementation at 1.5 mg/kg of P. polymyxa AM20 in feed, which increased body gain by 9% compared to control.
Japanese quail received feed diets treated with 0.5, 1.0, and 1.5 mg/kg of a Bc+Pp mixture (1:1).
In one patent application describing a poultry dietary supplement, at least 0.5 mL of the antimicrobial cell culture supernatant per kg of chicken feed was reported as the effective addition rate.
In a food safety research context, P. polymyxa OSY-HG produced up to 32 mg paenibacillin/L of milk during fermentation.

No human clinical dosage data exist. None of the identified peer-reviewed sources report a tested or established dosage of P. polymyxa whole cells or spore preparations in human subjects.

Safety Considerations

General Non-Pathogenicity

Paenibacillus polymyxa (formerly Bacillus polymyxa) is a non-pathogenic and endospore-forming bacterium. P. polymyxa is a Gram-positive, non-pathogenic soil bacterium. This characterization is widely cited in the biotechnology literature as a rationale for its use in industrial and agricultural settings.

Canadian Federal Government Risk Assessment

The Ministers of Environment and of Health of Canada conducted a screening assessment on Paenibacillus polymyxa strains ATCC 842, ATCC 55407, and 13540-4, concluding that these strains do not meet the criteria under paragraph 64(c) of CEPA 1999 as they are not entering the environment in a quantity or concentration or under conditions that constitute or may constitute a danger in Canada to human life or health.

Endospore Durability: A Consideration in Food Contexts

The endospores of P. polymyxa exhibit remarkable resilience, enabling them to withstand harsh environmental conditions such as high temperatures, biocides, pressure, and UV radiation; this durability enables the endospores to survive processes like pasteurization and persist in industrial equipment. In the context of dairy technology, this property is considered a food spoilage concern rather than a direct human health hazard, but it does complicate quality control in fermented or heat-treated food products.

Genus-Level Opportunistic Infection Risk

On the negative side, while Paenibacillus larvae is the causative agent of American Foulbrood (a lethal disease of honeybees), a variety of Paenibacillus species are opportunistic infectors of humans, and others cause spoilage of pasteurized dairy products. The Canadian government screening assessment includes a table of human case reports involving other Paenibacillus species, though cases specifically attributable to P. polymyxa itself are not common in the medical literature.

Polymyxin Gene Harboring and Antibiotic Resistance Concerns

Utilizing the antimicrobial agents produced by P. polymyxa in the pharmaceutical industry for clinical applications requires overcoming challenges related to achieving pure and large-scale production of antibiotics. Of particular regulatory concern is the fact that all sequenced P. polymyxa strains harbor gene clusters encoding polymyxins. Due to emerging issues with the re-use and side effects of last-resort polymyxin antibiotics, and the occurrence of insects resistant to Bacillus thuringiensis toxins, attention has recently turned to other Bacillales species including P. polymyxa as sources of novel antimicrobials. The potential for P. polymyxa carrying antibiotic biosynthesis genes to contribute to environmental antibiotic resistance gene pools is an area of active scientific discussion.

Nephrotoxicity and Neurotoxicity: Purified Polymyxins (Not the Whole Organism)

When polymyxin-class antibiotics are purified and administered as pharmaceutical drugs (not as the whole organism), toxicity is documented. By the early 1970s, the use of both polymyxin B and colistin was largely discontinued because of their significant neurotoxicity and nephrotoxicity. Polymyxins are considered as last-resort therapies to treat MDR bacteria, but their associated nephrotoxicity and neurotoxicity calls for the development of safer polymyxin therapy until novel and less toxic antibiotics are discovered. These toxicity profiles are attributed to the purified pharmaceutical agents, not to ingestion of the producing organism as a probiotic.

Absence of Human Clinical Trials

No controlled human clinical safety or efficacy trials of P. polymyxa as a dietary supplement have been identified in the peer-reviewed literature at the time of writing. The existing animal studies cannot substitute for human pharmacokinetics, safety profiling, or dose-ranging data. Due to its prolific secondary metabolism, manifold plant growth-promoting potentials, probiotic status, and bioremediation activities, P. polymyxa has attracted growing research interest, but this interest has not yet produced human-subject clinical data.

Summary of Evidence Strength

Antimicrobial compound production (polymyxins, fusaricidins, tridecaptin, paenibacillin): Well-established in vitro and pharmaceutical-level evidence.
Agricultural biocontrol and biofertilization: Substantial in vitro, greenhouse, and field-trial evidence across multiple peer-reviewed publications.
Probiotic effects in poultry and aquaculture: Preliminary; multiple small controlled animal studies with positive results, but high heterogeneity in strains, dosages, and endpoints. No human data.
Human health benefits as a dietary supplement: Not established. No human clinical trials have been published.
Safety in humans: Broadly considered non-pathogenic in regulatory assessments; endospore survival in food and potential antibiotic gene harboring represent considerations that warrant continued surveillance.

References

Health Conditions

Health conditions that Paenibacillus polymyxa may help support.

No conditions available.

Body Systems

Body systems that Paenibacillus polymyxa may help support.

No body systems available.